Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
Open Access
- 23 September 2024
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 31 (9) , 5709-5721
Abstract
Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell cycle and induction of proapoptotic activity. However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA). In severe cases, docetaxel causes persistent or permanent CIA (pCIA) when hair does not grow back completely six months after chemotherapy cessation. Hair loss has severe negative impacts on patients’ quality of life and may even compromise their compliance with treatment. This review discusses the notable prevalence of docetaxel-induced CIA and pCIA, as well as their prevention and management. At this moment, scalp cooling is the standard of care to prevent CIA. Treatment options to promote hair regrowth include but are not limited to minoxidil, photobiomodulation (PBMT), and platelet-rich plasma (PRP). In addition, a handful of current clinical trials are exploring additional agents to treat or prevent CIA. Research models of CIA, particularly ex vivo human scalp HF organ culture and in vivo mouse models with human scalp xenografts, will help expedite the translation of bench findings of CIA prevention and/or amelioration to the clinic.Keywords
Funding Information
- NIH/NCI (1R21CA277418, 1R01CA286527, 24B14)
- Florida Department of Health (1R21CA277418, 1R01CA286527, 24B14)
This publication has 99 references indexed in Scilit:
- Retrospective evaluation of Penguin Cold Caps for chemotherapy-induced alopeciaSupportive Care in Cancer, 2024
- Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2022
- “Dear hair loss”—illness perceptions of female patients with chemotherapy-induced alopeciaSupportive Care in Cancer, 2022
- Preventive effect of edaravone ointment on cyclophosphamide-chemotherapy induced alopeciaSupportive Care in Cancer, 2021
- Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast CancerJAMA Dermatology, 2020
- Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy AlopeciaJAMA Dermatology, 2019
- Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysisBreast Cancer Research and Treatment, 2017
- Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled StudiesAesthetic Plastic Surgery, 2014
- Low‐level laser (light) therapy (LLLT) for treatment of hair lossLasers in Surgery and Medicine, 2013
- Low-level laser treatment accelerated hair regrowth in a rat model of chemotherapy-induced alopecia (CIA)Lasers in Medical Science, 2012